**RESEARCH LETTER**

Inclusion of latent tuberculosis infection as a separate entity into the international classification of diseases

The 11th revision of the International Classification of Diseases (ICD-11) proposed by the WHO is currently in the consultation phase. In common with previous versions of the ICD this revised version does not contain a code for latent tuberculosis infection (LTBI), contrasting with the inclusion of a large number of codes for various manifestations of active tuberculosis (TB). Inclusion of a separate code for LTBI into ICD-11 is critically important for epidemiological, clinical and research purposes. On behalf of the Paediatric Tuberculosis Network European Trialsgroup, we encourage colleagues worldwide who are caring for TB patients or are involved in TB research to join us in supporting the case for a long overdue ICD code for LTBI.

We would like to draw your readers’ attention to the fact that the 11th revision of the International Classification of Diseases (ICD-11) proposed by the WHO is currently out for consultation. In common with previous versions of the ICD, this revised version does not contain a code for latent tuberculosis infection (LTBI). This contrasts with the inclusion of an extensive and complex coding system for various manifestations of active tuberculosis (TB) disease, including rather obscure entities such as ‘involvement of eyelid in TB’.

The true burden of LTBI is largely unknown, although WHO estimates suggest that a third of the global population has LTBI. However, with a few exceptions, reporting of TB worldwide only extends to cases with active TB, and consequently the true prevalence of LTBI in both adults and in children remains uncertain. Since cases with LTBI are ultimately the ‘reservoir’ perpetuating the ongoing TB pandemic, diagnosis and treatment of LTBI to prevent progression to active TB has been declared a key component in the WHO Global Plan to Stop TB.

We believe that the inclusion of a separate code for LTBI is of critical importance to (i) define the burden of LTBI more accurately; (ii) allow identification of LTBI cases from existing clinical databases to facilitate reimbursement of care and medication provided; and planning of clinical services, and (iii) enable epidemiological and laboratory-based TB research focusing on improving our understanding of LTBI.

The Paediatric Tuberculosis Network European Trialsgroup, comprising clinicians, epidemiologists and researchers from 23 European countries, has recently submitted a proposal to the WHO suggesting the addition of a separate ICD code for LTBI. We proposed that LTBI should be defined as a positive immunological test result (either tuberculin skin test or interferon-gamma release assay) in the absence of active TB.

We are aware that this definition has limitations, but in the absence of a gold standard for the diagnosis of LTBI embarking on complex definitions is unlikely to be useful in this context. Furthermore, we believe that such a deliberately broad definition is needed to allow clinicians involved in case management to make the decision on an individual patient basis as to whether LTBI is likely, by taking into account several factors that are difficult to quantify, including the patient’s cumulative risk of exposure to Mycobacterium tuberculosis.

We strongly encourage our colleagues worldwide who are involved in the care of TB patients or TB research to register as individual or group stakeholders via the ICD-11 Beta website (http://apps.who.int/classifications/icd11/browse/), and join us in supporting the case for a much-needed ICD code for LTBI. Together we can help shape ICD-11 and make an important change happen that has been long overdue.

Marc Tebruegge,1,2,6 Eva Salo,7 Nicole Ritz,5 Beate Kampmann,6,7 On behalf of the Paediatric Tuberculosis Network European Trialsgroup (pbtnt)

1 Academic Unit of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
2 Institute for Life Sciences, University of Southampton, Southampton, UK
3 Department of Paediatrics, Faculty of Medicine, The University of Melbourne, Parkville, Australia
4 Children’s Hospital, University of Helsinki, Helsinki, Finland
5 Paediatric Infectious Diseases Unit, University Children’s Hospital Basel, Basel, Switzerland
6 Academic Department of Paediatrics, Faculty of Medicine, Imperial College, London, UK
7 MRC Unit, The Gambia

Correspondence to Dr Marc Tebruegge, National Institute for Health Research Clinical Lecturer, Wellcome Trust Clinical Research Facility (Malipoint 218), University Hospitals Southampton NHS Trust, Tremena Road, Southampton SO16 6YD, UK; m.tebruegge@soton.ac.uk

Contributors MT and ES drafted the first version of the letter. MT, ES, NR and BK revised the letter for intellectual contents. All authors approved the final version prior to submission.

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

Accepted 5 October 2012

Thorax 2012;67: doi:10.1136/thoraxjnl-2012-202824

REFERENCES
